CORDIS
EU research results

CORDIS

English EN

MEFISTO - Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy

Objective

MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy knee osteoarthritis (OA) in Europe. Morphological profiling will identify the population of patients who, after meniscal resection, are at higher risk of early compartment degeneration, providing a personalized approach for the patient. The two different reconstructive strategies are: i) a controlled vascularized bioactive biodegradable meniscal scaffold, which will regenerate the native meniscus. This strategy will address younger patients with early osteoarthritic changes. ii) a bioactive non-biodegradable meniscal prosthesis, which will act as a mechanical unloading device and a drug delivery system, with the capacity to modulate the inflammatory environment. This strategy will address patients with advanced OA. A socio-economic analysis of the efficacy of existing meniscal substitutes will complete the project. This analysis is of vital importance for the European healthcare system, as it will provide a clear understanding of the costs and benefits of current clinical practice and predict the impact of the two new interventions. The technological innovation lies in the development of biologically active functionalized nanobiomaterials that can interact with the surrounding articular tissues. The biodegradable scaffold will promote revascularization in the peripheral zone, while leaving the inner zone avascular, reflecting the native meniscal tissue and functionalization with drug delivery micro/nanoparticles of the non-biodegradable device will provide modulation of inflammation. The impact is expected to be significant as so many patients have undergone or will undergo meniscectomy. The interventions developed in MEFISTO will prevent these patients from receiving joint-sacrificing procedures such as metal prosthesis whilst reducing the social burden, associated costs and high levels of morbidity resulting from OA.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

GEISTLICH BIOMATERIALS VERTRIEBSGESELLSCHAFT MBH

Address

Schneidweg 5
76534 Baden-Baden

Germany

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 361 250

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

HUMANITAS UNIVERSITY

Italy

EU Contribution

€ 847 375

KLINIKUM DER UNIVERSITAET REGENSBURG

Germany

EU Contribution

€ 543 750

TISSUE CLICK LTD

United Kingdom

EU Contribution

€ 381 250

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA

Spain

EU Contribution

€ 482 197,50

UNIVERSITEIT ANTWERPEN

Belgium

EU Contribution

€ 498 562,50

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 461 875

ORTHOKEY ITALIA SRL

Italy

EU Contribution

€ 253 125

ETABLISSEMENT FRANCAIS DU SANG

France

EU Contribution

€ 216 875

ACTIVE IMPLANTS BV

Netherlands

EU Contribution

€ 852 762,50

AIM GMBH - ASSESSMENT IN MEDICINE RESEARCH AND CONSULTING

Germany

EU Contribution

€ 248 125

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 559 442,50

SCIPROM SARL

Switzerland

EU Contribution

€ 290 000

Project information

Grant agreement ID: 814444

Status

Ongoing project

  • Start date

    1 April 2019

  • End date

    30 November 2023

Funded under:

H2020-EU.2.1.3.

H2020-EU.2.1.2.

  • Overall budget:

    € 5 996 590

  • EU contribution

    € 5 996 590

Coordinated by:

GEISTLICH BIOMATERIALS VERTRIEBSGESELLSCHAFT MBH

Germany